MarginsXMarginsX
Home › Markets › IPHYF

Innate Pharma SA (IPHYF)

IPHYF is quoted over the counter, not listed on an exchange. Innate Pharma SA files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · October 2, 2026
$1.51
No trades since Oct 2, 2026; later closes repeat the last quote
1-year return
-24.6%
Market cap
The company also trades on Nasdaq as IPHA; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On fiscal year to December 31, 2025 (20-F)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerIPHYF, quoted over the counter
SEC CIK0001598599
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codeBiological Products, (No Diagnostic Substances)
Business addressMarseille
Incorporated inFrance

Warning signs

Cash runway
6.4 months
28.1M EUR cash at December 31, 2025
Share count, 1 year
+11.8%
2024-12-31 to 2025-12-31 · +17.8% over 3 years
Going-concern doubt
Yes
20-F filed April 1, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions and events raise material uncertainty (or raise substantial doubt as contemplated by PCAOB standards) on the Company's ability to continue as a going concern."
20-F 2026-04-01
Cash and burn28.1M EUR cash; operating cash flow -13.2M EUR a quarter.Report 2025-12-31
Shares outstanding93,719,323 (2025-12-31); 83,830,336 a year earlier; 79,542,627 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Associés, Le Bouscat, FrancePCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
9.0M EUR-49.2M EUR-52.8M EUR28.1M EURNo debt tags9.0M EUR20-F 2026-04-01
FY 2024
2024-12-31
20.1M EUR-49.5M EUR-6.9M EUR66.4M EURNo debt tags20.1M EUR20-F 2026-04-01
FY 2023
2023-12-31
61.6M EUR-7.6M EUR-32.6M EUR70.6M EURNo debt tags61.6M EUR20-F 2026-04-01
FY 2022
2022-12-31
57.7M EUR-58.1M EUR-19.2M EUR84.2M EURNo debt tags57.7M EUR20-F 2025-04-30
FY 2021
2021-12-31
24.7M EUR-52.8M EUR-58.5M EUR103.8M EURNo debt tags24.7M EUR20-F 2024-04-04
FY 2020
2020-12-31
69.8M EUR-64.0M EUR-51.8M EUR136.8M EURNo debt tags69.8M EUR20-F 2023-04-06
FY 2019
2019-12-31
85.4M EUR-20.8M EUR34.9M EUR202.9M EURNo debt tags85.4M EUR20-F 2022-04-04
FY 2018
2018-12-31
94.0M EUR3.0M EUR-32.5M EUR152.3M EURNo debt tags94.0M EUR20-F 2021-04-27

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-02-06
Latest annual report20-F2026-04-01
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 340 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier